Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised…
By H. Wilke, K. Muro, E. Van Cutsem, S. Oh, G. Bodoky, Y. Shimada, S. Hironaka, N. Sugimoto, O. Lipatov, Tae-You Kim and 10 more. The Lancet Oncology, 2014
2,137 citations recorded by the source corpus.
Subfields: Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/46da2638cb0df7d48c99d73d7419063cb4b037ad
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- Japanese gastric cancer treatment guidelines 2014 (ver. 4) (2016, background): “(Additional comments in this English edition) Following the results of the RAINBOW trial [27] and the REGARD trial [28], paclitaxel ? ramucirumab emerged as a new standard of care and was rated as recommendation category 1 in the second-line setting, while ramucirumab monotherapy was Japanese gastri”
- Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Ramucirumab significantly increased OS in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma in two international multicentric Phase III studies, REGARD 142 and RAINBOW 143 , and was approved by the FDA for this indication in 2014.”
- Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) (2022, background): “Since the paclitaxel/ramucirumab combination was shown to be superior to weekly paclitaxel monotherapy in a phase III trial (RAINBOW trial) [69], this regimen is currently the “Recommended regimen” (CQ16).”